EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients

Hannah Gagg iD, Sophie T Williams iD, Samantha Conroy, Katie N Myers iD, Connor McGarrity-Cottrell, Callum Jones iD, Thomas Helleday, Juha Rantala, Ola Rominiyi, Sarah J Danson, Spencer J Collis iD, Greg Wells

F1000Research · 2024

DOI: 10.12688/f1000research.135809.2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift F1000Research, 2024. Verfasst von Hannah Gagg und 11 weiteren Autor:innen. Beteiligte Einrichtung: Oncology & Metabolism, The University of Sheffield, Sheffield, England, S10 2RX, UK. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Glioblastoma, Precision Medicine, Glioma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain Tumour Charity, Urology Foundation, National Centre for the Replacement Refinement and Reduction of Animals in Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With diminishing returns and high clinical failure rates from traditional preclinical and animal-based drug discovery strategies, more emphasis is being placed on alternative drug discovery platforms. Ex vivo approaches represent a departure from both more traditional preclinical animal-based models and clinical-based strategies and aim to address intra-tumoural and inter-patient variability at an earlier stage of drug discovery. Additionally, these approaches could also offer precise treatment stratification for patients within a week of tumour resection in order to direct tailored therapy. One tumour group that could significantly benefit from such ex vivo approaches are high-grade gliomas, which exhibit extensive heterogeneity, cellular plasticity and therapy-resistant glioma stem cell (GSC) niches. Historic use of murine-based preclinical models for these tumours has largely failed to generate new therapies, resulting in relatively stagnant and unacceptable survival rates of around 12-15 months post-diagnosis over the last 50 years. The near universal use of DNA damaging chemoradiotherapy after surgical resection within standard-of-care (SoC) therapy regimens provides an opportunity to improve current treatments if we can identify efficient drug combinations in preclinical models that better reflect the complex inter-/intra-tumour heterogeneity, GSC plasticity and inherent DNA damage resistance mechanisms. We have therefore developed and optimised a high-throughput ex vivo drug screening platform; GliExP, which maintains GSC populations using immediately dissociated fresh surgical tissue. As a proof-of-concept for GliExP, we have optimised SoC therapy responses and screened 30+ small molecule therapeutics and preclinical compounds against tumours from 18 different patients, including multi-region spatial heterogeneity sampling from several individual tumours. Our data therefore provides a strong basis to build upon GliExP to incorporate combination-based oncology therapeutics in tandem with SoC therapies as an important preclinical alternative to murine models (reduction and replacement) to triage experimental therapeutics for clinical translation and deliver rapid identification of effective treatment strategies for individual gliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsGlioblastomaPrecision MedicineGliomaBrain NeoplasmsAntineoplastic AgentsAnimalsHumansMiceDrug Screening Assays, AntitumorAvatar

Stichwörter der Autor:innen

GliExPGlioblastomacancer therapeuticsex vivo drug screeningfunctional precision medicineglioma stem cells

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Oncology & Metabolism, The University of Sheffield, Sheffield, England, S10 2RX, UK.
  • Neurosurgery, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK.
  • Urology, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK.
  • Karolinska Institut, Solnavägen, Solna, 171 77, Sweden.
  • Misvik Biology Ltd, Karjakatu, Turku, FI-20520, Finland.
  • Weston Park Hospital, Sheffield, S10 2SJ, UK.

ORCID-Profile: Hannah Gagg, Sophie T Williams, Katie N Myers, Callum Jones, Spencer J Collis

Förderung

  • Brain Tumour Charity
  • Urology Foundation
  • National Centre for the Replacement Refinement and Reduction of Animals in Research

Zitieren

APA

Gagg, H., Williams, S. T., Conroy, S., Myers, K. N., McGarrity-Cottrell, C., Jones, C., Helleday, T., Rantala, J., Rominiyi, O., Danson, S. J., Collis, S. J., & Wells, G. (2024). Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research. https://doi.org/10.12688/f1000research.135809.2

Vancouver

Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, et al. Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research. 2024. doi:10.12688/f1000research.135809.2

BibTeX
@article{Gagg2024,
  author = {Gagg, Hannah and Williams, Sophie T and Conroy, Samantha and Myers, Katie N and McGarrity-Cottrell, Connor and Jones, Callum and Helleday, Thomas and Rantala, Juha and Rominiyi, Ola and Danson, Sarah J and Collis, Spencer J and Wells, Greg},
  title = {Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients},
  journal = {F1000Research},
  year = {2024},
  doi = {10.12688/f1000research.135809.2}
}
Kostenlos starten →